Human Leukocyte Antigen Alleles and Cytomegalovirus Infection After Renal Transplantation

Background: Several studies have been conducted on the relationship between a number of human leukocyte antigen (HLA) alleles and cytomegalovirus infection (CMV), in kidney transplant recipients, after transplantation. However, only a limited number of HLAs have been investigated, so far, and the results have been contradictory. Objectives: This study aimed to investigate the relationship between 59 HLA alleles and the CMV infection, in transplant recipients, after kidney transplantation. Patients and Methods: This retrospective cohort study was conducted on 200 patients, receiving a kidney transplant, in Baqiyatallah Hospital, in Tehran, during 2013. Throughout a one-year follow-up of kidney transplant recipients, in case of detecting the CMV antigen in patients’ blood, at any time, they were placed in the group of patients with CMV infection, whereas, if no CMV-specific antigen was developed, over a year, patients were placed in the group of patients without CMV infection, after transplantation. This study investigated the relationship between CMV infection in kidney transplant recipients and 59 HLA alleles, including 14 HLA-A, 28 HLA-B, and 17 HLA-DRB1 cases. Results: Of all participants, 104 patients (52%) were diagnosed with CMV infection. There was no significant difference between the two groups, with and without CMV infection, in terms of patient’s characteristics. The CMV infection, in patients receiving a transplanted organ from deceased donor, was significantly more prevalent than in those receiving kidney transplant from living donor (63% vs. 39%, respectively, P = 0.001). Recipients with HLA-B44 were more infected with CMV compared with patients without this allele (80% vs. 50%, respectively, P = 0.024); on the contrary, kidney recipients with HLA-DRB1-1 were less infected with CMV than patients without this allele (31% vs. 55%, respectively, P = 0.020). There was no significant relationship between CMV infection and other HLA alleles. Results of multivariate logistic regression analysis showed that deceased donor renal transplantation (OR = 3.018, 95%CI: 1.662 - 5.480, P < 0.001), presence of HLA-B44 (OR = 4.764, 95%CI: 1.259 - 18.032, P = 0.022) and lack of HLA-B8 (OR = 3.246, 95%CI: 1.030 - 10.230, P = 0.044) were the independent risk factors for developing CMV infection, after kidney transplantation. Conclusions: The findings of this study showed that deceased donor renal transplantation and the presence of HLA-B44 can make the kidney recipient susceptible to CMV infection after kidney transplantation; on the other hand, the presence of HLA-B8 can have a protective effect.

[1]  R. Inman,et al.  The Application of Clinical Genetics Dovepress the Genetic Basis of Ankylosing Spondylitis: New Insights into Disease Pathogenesis , 2022 .

[2]  M. Haberal,et al.  Cytomegalovirus infection in renal transplant recipients: one center's experience. , 2013, Transplantation proceedings.

[3]  Wei Jiang,et al.  On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes , 2012, Expert Reviews in Molecular Medicine.

[4]  R. Wyse,et al.  Cellular and molecular aspects of Goodpasture syndrome. , 2012, Iranian journal of kidney diseases.

[5]  Renan Rangel Bonamigo,et al.  HLA and skin cancer. , 2012, Anais brasileiros de dermatologia.

[6]  J. Gaudart,et al.  Cytomegalovirus risk factors in renal transplantation with modern immunosuppression , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[7]  F. Luan,et al.  Choice of induction regimens on the risk of cytomegalovirus infection in donor‐positive and recipient‐negative kidney transplant recipients , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[8]  J. Fishman,et al.  Infectious complications of antilymphocyte therapies in solid organ transplantation. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Zunt,et al.  Diagnosis of neurocysticercosis by detection of Taenia solium DNA using a global DNA screening platform. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Korbonits,et al.  HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. Fishman.  Infection in solid-organ transplant recipients. , 2007, The New England journal of medicine.

[12]  R. Kaslow,et al.  HLA‐B, ‐DRB1/3/4/5, and ‐DQB1 gene polymorphisms in human immunodeficiency virus‐related Kaposi's sarcoma , 2005, Journal of Medical Virology.

[13]  M. Crespo,et al.  Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  B. Alexander,et al.  Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients , 2004, Transplantation.

[15]  S. Fuggle,et al.  ISCHAEMIC PRECONDITIONING TO CADAVER DONOR LIVERS PROTECTS ALLOGRAFTS AND REDUCES INFLAMMATORY CHANGES AFTER REPERFUSION , 2004 .

[16]  A. Pacheco-Silva,et al.  Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies , 2004, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  M. Stegall,et al.  PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1 , 2004, Transplantation.

[18]  Y. Lebranchu,et al.  Induction therapy by anti‐thymocyte globulin (rabbit) in renal transplantation: a 1‐yr follow‐up of safety and efficacy , 2003, Clinical transplantation.

[19]  K. Wucherpfennig.  MHC‐Linked Susceptibility to Type 1 Diabetes , 2003 .

[20]  C. Retière,et al.  Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection , 2003, Transplantation.

[21]  K. Wucherpfennig.  MHC-linked susceptibility to type 1 diabetes: a structural perspective. , 2003, Annals of the New York Academy of Sciences.

[22]  R. Stratta,et al.  Patterns of cytomegalovirus infection in simultaneous kidney–pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[23]  W. Sułowicz,et al.  [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients]. , 2001, Przeglad lekarski.

[24]  A. Davenport,et al.  Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. , 1993, Kidney international.

[25]  R. Rubin.  Infectious disease complications of renal transplantation. , 1993, Kidney international.

[26]  J. Alvarez-Grande,et al.  Absence of association between HLA-DR7 and cytomegalovirus infection in renal transplant patients , 1993, The Lancet.

[27]  J. Hooff,et al.  Increased frequency of CMV infection in HLA-DR7 matched renal allograft recipients , 1993, The Lancet.

[28]  E. Pollitt,et al.  Reversal of developmental delays in iron-deficient anaemic infants treated with iron , 1993, The Lancet.

[29]  A. Sommer,et al.  Abnormal T-cell subset proportions in vitamin-A-deficient children , 1993, The Lancet.

[30]  J. Soulillou,et al.  THE INFLUENCE OF HLA A‐B‐DR MATCHING ON CYTOMEGALOVIRUS DISEASE AFTER RENAL TRANSPLANTATION: Evidence That HLA‐Dr7‐Matched Recipients Are More Susceptible to Cytomegalovirus Disease , 1992, Transplantation.